Mojtaba Baktashian1, Sara Saffar Soflaei2, Negin Kosari3, Mansoor Salehi4, Alireza Khosravi5, Maliheh Ahmadinejad6, Mohsen Moohebati7, Mahmood Ebrahimi8, Farzad Rahmani9, Ramin Khameneh-Bagheri10, Mostafa Ahmadi11, Fatemeh Sadabadi12, Maryam Tayefi13, Suzan Bazhdanzadeh14, Gordon A Ferns15, Seyed Mohammad Hashemi16, Alireza Pasdar17, Majid Ghayour-Mobarhan18. 1. Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Modern Sciences & Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: BaktashianM911@mums.ac.ir. 2. Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Modern Sciences & Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: Saffars911@mums.ac.ir. 3. Department of Modern Sciences & Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Department of Genetics, Faculty of Medicine and Genetics Laboratory, AL Zahra Hospital, Isfahan University of Medicine, Isfahan, Iran. Electronic address: M_salehi@med.mui.ac.ir. 5. Isfahan Cardiovascular Research Institute, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. 6. Department of Clinical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 7. Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.. Electronic address: MouhebatiM@mums.ac.ir. 8. Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.. Electronic address: EbrahimiMH@mums.ac.ir. 9. Biochemistry of Nutrition Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: RahmaniF931@mums.ac.ir. 10. Assistant Professor, Department of Cardiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: KhamenehBR@mums.ac.ir. 11. Assistant Professor, Department of Cardiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: AhmadiMS@mums.ac.ir. 12. Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Modern Sciences & Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: SadabadiF2@mums.ac.ir. 13. Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Clinical Research Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: TayefiM@mums.ac.ir. 14. Supervisor of Heart Center, Sa'adi Hospital, Isfahan, Iran. 15. Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK. Electronic address: G.Ferns@bsms.ac.uk. 16. Department of Cardiology, Chamran Hospital, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: Hashemi1344@gmail.com. 17. Department of Modern Sciences & Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: PasdarA@mums.ac.ir. 18. Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: GhayourM@mums.ac.ir.
Abstract
BACKGROUND: In-stent restenosis (ISR) is one adverse outcome of coronary stent implantation. Although using drug-eluting stents has reduced the rate of ISR, it remains a major problem. Here, we have investigated the relationship between several patient characteristics including serum high sensitive C-reactive protein (hs-CRP) and ISR. METHODS: This was a case-control study comprising 104 individuals with ISR and 202 patients without. Baseline characteristics were collected using a questionnaire. Fasting blood glucose (FBG), serum triglycerides (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and serum high sensitivity C-reactive protein (hs-CRP) were measured using commercial kits on an auto-analyzer. Data were analyzed using SPSS software and a p value ≤ 0.05 was considered significant. RESULTS: Diabetes mellitus (p < 0.001), stent type (p = 0.005), serum hs-CRP (p = 0.006), FBG (p = 0.038) and serum TG (p = 0.039) were significantly associated with ISR. The association between hs-CRP and ISR remained significant after adjustment for stent type and DM. For patients with a serum hs-CRP <2.64 mg/dL, ISR was only associated with diabetes mellitus (p = 0.016); while for individuals with a serum hs-CRP ≥2.64 mg/dL, ISR was also associated with the presence of diabetes mellitus, serum triglycerides and stent type. CONCLUSION: Higher levels of serum hs-CRP were significantly associated with the occurrence of ISR.
BACKGROUND: In-stent restenosis (ISR) is one adverse outcome of coronary stent implantation. Although using drug-eluting stents has reduced the rate of ISR, it remains a major problem. Here, we have investigated the relationship between several patient characteristics including serum high sensitive C-reactive protein (hs-CRP) and ISR. METHODS: This was a case-control study comprising 104 individuals with ISR and 202 patients without. Baseline characteristics were collected using a questionnaire. Fasting blood glucose (FBG), serum triglycerides (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and serum high sensitivity C-reactive protein (hs-CRP) were measured using commercial kits on an auto-analyzer. Data were analyzed using SPSS software and a p value ≤ 0.05 was considered significant. RESULTS:Diabetes mellitus (p < 0.001), stent type (p = 0.005), serum hs-CRP (p = 0.006), FBG (p = 0.038) and serum TG (p = 0.039) were significantly associated with ISR. The association between hs-CRP and ISR remained significant after adjustment for stent type and DM. For patients with a serum hs-CRP <2.64 mg/dL, ISR was only associated with diabetes mellitus (p = 0.016); while for individuals with a serum hs-CRP ≥2.64 mg/dL, ISR was also associated with the presence of diabetes mellitus, serum triglycerides and stent type. CONCLUSION: Higher levels of serum hs-CRP were significantly associated with the occurrence of ISR.
Authors: Grzegorz K Jakubiak; Natalia Pawlas; Grzegorz Cieślar; Agata Stanek Journal: Int J Environ Res Public Health Date: 2021-11-15 Impact factor: 3.390